Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Henry Wong

CredentialsMD,PhD
TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentDermatology, College of Medicine
Address324 UAMS Campus Dr.
Mail Slot # 576
Little Rock AR 72205
Phone501-686-5111
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Henry K. Wong, M.D., Ph.D. is Professor and Chairman of the University of Arkansas for Medical Sciences Department of Dermatology. Dr. Wong comes to UAMS from Ohio State University Medical Center in Columbus, Ohio, where he was director of immunodermatology and co-director of a multi-disciplinary cutaneous lymphoma clinic at the James Cancer Hospital and Comprehensive Cancer Center. He was also director of the psoriasis clinic, dermatology clinical trials, and the medical dermatology research fellowship at Ohio State. He is nationally known for his expertise on cutaneous T-cell lymphoma.Dr. Wong received his medical and doctoral degrees in biochemistry at New York University School of Medicine and the Sackler Institute of Graduate Biomedical Sciences in New York, NY. He was an intern at Barnes Hospital and the Washington University School of Medicine in St. Louis. Dr. Wong completed his residency in dermatology at Bellevue Hospital and New York University and was a visiting research fellow in immunology at the Cornell University School of Medicine.Wong has been chair of the Biomarker Committee of the U.S. Cutaneous Lymphoma Consortium since 2010, and became a member of the Clinical Guideline Committee of the American Academy of Dermatology in 2014. Since 2009, Dr. Wong has been recognized as one of the Best Doctors in Dermatology.Dr. Wong previously held faculty, research, and clinical positions at the Walter Reed Army Medical Center in Washington, D.C., as well as the Wayne State University School of Medicine and the Henry Ford Health System in Detroit.


    Collapse Biography 
    Collapse Leadership and Administrative Roles
    Director, Cutaneous Lymphoma Clinic

    Dermatology Research

    Collapse credentials

    Collapse Research 
    Collapse research activities and funding
    I01CX001895     (WONG, HENRY KEUNG)Apr 1, 2020 - Mar 31, 2024
    NIH
    Epigenetic Regulation of Differentially Expressed Genes in Cutaneous T Cell Lymphoma
    Role: Principal Investigator
    RD.06.SPR.118161     (WONG, HENRY)Mar 25, 2020
    Galderma - Pass Through: Syneos Health
    A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderateto-Severe Atopic Dermatitis (249958)
    Role: Principal Investigator
    M16-046     (WONG, HENRY)Jan 31, 2020
    AbbVie Inc
    A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermatitis (IRB 239608)
    Role: Principal Investigator
    KPL     (WONG, HENRY)Nov 22, 2019 - Jan 15, 2020
    Kiniksa Pharmaceuticals, Ltd.
    KPL-716-C202: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Pilot Study to Investigate the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Diseases Characterized by Chronic Pruritus (IRB 249909)
    Role: Principal Investigator
    KPL-716-C202     (WONG, HENRY)Nov 22, 2019 - Jan 15, 2020
    Kiniksa Pharmaceuticals, Ltd.
    KPL-716-C202: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Pilot Study to Investigate the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Diseases Characterized by Chronic Pruritus (IRB 249909)
    Role: Principal Investigator
    KPL-716-C201     (WONG, HENRY)Nov 22, 2019
    Kiniksa Pharmaceuticals, Ltd. - Pass Through: Innovaderm Research, Inc.
    KPL-716-C201: A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects with Prurigo Nodularis (IRB 239539)
    Role: Principal Investigator
    R3500-AD     (WONG, HENRY)Sep 26, 2019
    Regeneron Pharmaceuticals - Pass Through: PAREXEL International LLC
    A Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study to Assess the Efficacy and Safety of REGN3500 Monotherapy, and Combination of REGN3500 Plus Dupilumab in Adult Patients with Moderate-to-Severe Atopic Dermatitis (229183)
    Role: Principal Investigator
    R3500-AD-1798     (WONG, HENRY)Sep 26, 2019
    Regeneron Pharmaceuticals - Pass Through: PAREXEL International LLC
    A Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study to Assess the Efficacy and Safety of REGN3500 Monotherapy, and Combination of REGN3500 Plus Dupilumab in Adult Patients with Moderate-to-Severe Atopic Dermatitis (229183)
    Role: Principal Investigator
    R3500-AD-1805     (WONG, HENRY)Sep 20, 2019
    Regeneron Pharmaceuticals - Pass Through: PAREXEL International LLC
    R3500-AD-1805 A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 229151
    Role: Principal Investigator
    M16     (VEERAPUTHIRAN, MUTHU)Jul 26, 2019
    AbbVie Inc
    Phase 1b Study of Venetoclax and Dinaciclib (MK7965) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (IRB 228481)
    Role: Principal Investigator
    E7777-G000     (WONG, HENRY)Dec 27, 2018
    Eisai
    A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma (IRB 228431)
    Role: Principal Investigator
    E7777-G000-302     (WONG, HENRY)Dec 27, 2018
    Eisai
    A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma (IRB 228431)
    Role: Principal Investigator
    HPN-CTCL     (WONG, HENRY)Oct 24, 2017 - Oct 25, 2020
    Soligenix, Inc.
    SGX301- A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma
    Role: Principal Investigator
    HPN-CTCL-01     (WONG, HENRY)Oct 24, 2017 - Oct 25, 2020
    Soligenix, Inc.
    SGX301- A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma
    Role: Principal Investigator
    EL     (WONG, HENRY)Jul 11, 2017 - Jun 22, 2020
    Elorac, Inc.
    Evaluate the safety and efficacy of topical naloxone hydrochloride lotion, 0.5%, for the relief of pruritus in patients with the mycosis fungoides (MF) form of cutaneous t-cell lymphoma (CTCL)
    Role: Principal Investigator
    EL-1007-01-01     (WONG, HENRY)Jul 11, 2017 - Jun 22, 2020
    Elorac, Inc.
    Evaluate the safety and efficacy of topical naloxone hydrochloride lotion, 0.5%, for the relief of pruritus in patients with the mycosis fungoides (MF) form of cutaneous t-cell lymphoma (CTCL)
    Role: Principal Investigator
    CAIN457FUS01     (WONG, HENRY)Feb 6, 2017 - Feb 28, 2019
    NOVARTIS Pharmaceuticals Corporation
    CHOICE STUDY
    Role: Principal Investigator
    AIN457A2326     (WONG, HENRY K)Jan 17, 2017 - Jul 31, 2019
    NOVARTIS Pharmaceuticals Corporation
    CLARITY
    Role: Principal Investigator
    R21CA164911     (WONG, HENRY KEUNG)Jul 25, 2012 - Dec 30, 2014
    NIH
    Novel Biomarkers in Cutaneous T Cell Lymphoma
    Role: Principal Investigator
    R21AR052877     (WONG, HENRY KEUNG)Jul 17, 2006 - Jun 30, 2009
    NIH
    Gene expression abnormalities in mycosis fungoides
    Role: Principal Investigator
    K08AR047818     (WONG, HENRY KEUNG)Sep 20, 2002 - Jun 30, 2008
    NIH
    Gene expression in memory CD4+T cells.
    Role: Principal Investigator

    Collapse Identifiers 
    Collapse eRA Commons id
    hwong1
    Same Department Expand Description
    Search Department